Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Launched by WUHAN UNION HOSPITAL, CHINA · Aug 25, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called gastrodin on heart tissue damage in patients undergoing heart surgery, specifically those with a condition known as hypertrophic cardiomyopathy. The goal is to see if gastrodin can help protect the heart during surgery. Participants in the study will be divided into two groups: one group will receive gastrodin during their surgery, while the other group will not. Researchers will collect heart tissue samples and observe how well each group recovers after the surgery.

To be eligible for this trial, participants must be at least 18 years old and diagnosed with hypertrophic cardiomyopathy. They should be scheduled for certain types of heart surgery and be able to give their consent to participate. However, individuals with serious genetic diseases, severe malnutrition, ongoing infections, or significant health issues affecting the liver or kidneys will not be able to take part. Those who join the study can expect to be closely monitored for their recovery and the effects of the medication on their heart tissue.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with hypertrophic cardiomyopathy aged≥18 years, regardless of gender;
• • Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery;
• • Signed informed consent, good compliance.
• Exclusion Criteria:
• • suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.);
• • moderate to severe malnutrition, moderate to severe anemia;
• • persistent infection;
• • severe preoperative underlying diseases (such as severe liver and kidney dysfunction)